CROSSJECT Financials Crossject Deutsche Boerse AG
Equities
74C
FR0011716265
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.826 EUR | +2.70% |
|
+16.16% | -59.78% |
| 07-10 | Markets Powered by Alternating Current |  |
| 07-10 | Crossject Gets EUR7 Million Public Funding for New Epinephrine Product | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 46.16 | 77.73 | 78.44 | 99.04 | 189 | 84.68 | - | - |
| Enterprise Value (EV) 1 | 46.7 | 77.73 | 88.99 | 105.4 | 205.6 | 106.4 | 89.78 | 59.08 |
| P/E ratio | -6.48 x | -7.48 x | -6.95 x | -11 x | -21.6 x | -8.24 x | 3.96 x | 2.79 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.7 x | 13.6 x | 86 x | 104 x | 14.7 x | 10.5 x | 1.6 x | 1.25 x |
| EV / Revenue | 7.79 x | 13.6 x | 97.6 x | 110 x | 16 x | 13.1 x | 1.69 x | 0.87 x |
| EV / EBITDA | -9.64 x | -12.7 x | -12.1 x | -15.2 x | -33.6 x | -10.1 x | 2.75 x | 1.27 x |
| EV / FCF | - | - | - | - | -16.3 x | -8.44 x | 5.41 x | 1.92 x |
| FCF Yield | - | - | - | - | -6.13% | -11.8% | 18.5% | 52% |
| Price to Book | 15.4 x | -64.3 x | -13.4 x | 44.6 x | -35.7 x | -10.4 x | 6.38 x | 1.94 x |
| Nbr of stocks (in thousands) | 20,072 | 25,361 | 27,523 | 30,057 | 38,026 | 42,812 | - | - |
| Reference price 2 | 2.300 | 3.065 | 2.850 | 3.295 | 4.970 | 1.978 | 1.978 | 1.978 |
| Announcement Date | 26/03/20 | 30/03/21 | 24/03/22 | 20/03/23 | 02/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.994 | 5.731 | 0.912 | 0.954 | 12.83 | 8.1 | 53 | 68 |
| EBITDA 1 | -4.846 | -6.116 | -7.333 | -6.93 | -6.115 | -10.5 | 32.7 | 46.5 |
| EBIT 1 | -8.643 | -10.67 | -11.82 | -13.29 | -12.3 | -10.9 | 30.1 | 43.1 |
| Operating Margin | -144.19% | -186.22% | -1,296.38% | -1,392.87% | -95.9% | -134.57% | 56.79% | 63.38% |
| Earnings before Tax (EBT) | -8.533 | -10.92 | -12.52 | -13.38 | -11.33 | - | - | - |
| Net income 1 | - | - | - | - | -8.467 | -10.9 | 22.6 | 32.3 |
| Net margin | - | - | - | - | -66.01% | -134.57% | 42.64% | 47.5% |
| EPS 2 | -0.3551 | -0.4100 | -0.4100 | -0.3000 | -0.2300 | -0.2400 | 0.5000 | 0.7100 |
| Free Cash Flow 1 | - | - | - | - | -12.6 | -12.6 | 16.6 | 30.7 |
| FCF margin | - | - | - | - | -98.27% | -155.56% | 31.32% | 45.15% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 50.76% | 66.02% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 73.45% | 95.05% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 26/03/20 | 30/03/21 | 24/03/22 | 20/03/23 | 02/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 0.54 | - | 10.5 | 6.36 | 16.6 | 21.7 | 5.1 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | 25.6 |
| Leverage (Debt/EBITDA) | -0.1108 x | - | -1.439 x | -0.9172 x | -2.717 x | -2.067 x | 0.156 x | - |
| Free Cash Flow 1 | - | - | - | - | -12.6 | -12.6 | 16.6 | 30.7 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.1500 | -0.0500 | -0.2100 | 0.0700 | -0.1400 | -0.1900 | 0.3100 | 1.020 |
| Cash Flow per Share | -0.2700 | -0.2300 | -0.2300 | -0.1400 | - | - | - | - |
| Capex 1 | - | - | - | - | 6.4 | 0.3 | 2.1 | 2.7 |
| Capex / Sales | - | - | - | - | 49.92% | 3.7% | 3.96% | 3.97% |
| Announcement Date | 26/03/20 | 30/03/21 | 24/03/22 | 20/03/23 | 02/04/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.978
EUR
Average target price
4.3
EUR
Spread / Average Target
+117.39%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.50% | 261M |
- Stock Market
- Equities
- ALCJ Stock
- 74C Stock
- Financials Crossject
